Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.
Aripiprazole
Cox proportional hazards model
Kaplan–Meier
Long-term efficacy
Long-term tolerability
Olanzapine
Schizophrenia
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
24
12
2022
accepted:
12
06
2023
medline:
1
9
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
The long-term effectiveness of olanzapine and aripiprazole in real clinical conditions at flexible doses in patients after hospital discharge has not been evaluated yet. This study was a multicenter retrospective cohort study. Patients with schizophrenia (n = 398) were prescribed olanzapine (n = 303) or aripiprazole (n = 95) at hospital discharge. The continuation of olanzapine or aripiprazole at 26, 52, or 104 weeks after the hospital discharge were compared using a Cox proportional hazards model and adjusted for possible confounders. The Kaplan-Meier survival curves revealed that the continuation of olanzapine at 26 (P = 0.001) and 52 weeks (P = 0.018) was significantly higher than that of aripiprazole but not at 104 weeks. Olanzapine was better than aripiprazole in efficacy at 26 (hazard ratio: 0.321, 95% confidence interval: 0.159-0.645, P = 0.001), 52 (hazard ratio: 0.405, 95% confidence interval: 0.209-0.786, P = 0.008), and 104 weeks (hazard ratio: 0.438, 95% confidence interval: 0.246-0.780, P = 0.005). Aripiprazole was better than olanzapine in tolerability at 104 weeks (hazard ratio: 4.574, 95% confidence interval: 1.415-14.787, P = 0.011). Rates after two years continuation of olanzapine and aripiprazole were not significantly different in patients with less than five years' duration of illness, but olanzapine was more commonly maintained for more than two years in those patients who had been ill for over five years' due to its greater efficacy. Olanzapine treatment showed better continuation rates at 26 and 52 after hospital discharge than aripiprazole, whereas maintenance with the two antipsychotics did not differ significantly at 104 weeks, due reduced tolerability of long-term olanzapine treatment.
Identifiants
pubmed: 37460628
doi: 10.1007/s00213-023-06407-6
pii: 10.1007/s00213-023-06407-6
doi:
Substances chimiques
Aripiprazole
82VFR53I78
Olanzapine
N7U69T4SZR
Benzodiazepines
12794-10-4
Piperazines
0
Quinolones
0
Antipsychotic Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1911-1920Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B et al (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22:547–562. https://doi.org/10.2165/00023210-200822070-00002
doi: 10.2165/00023210-200822070-00002
pubmed: 18547125
Bak M, Fransen A, Janssen J et al (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9:e94112. https://doi.org/10.1371/JOURNAL.PONE.0094112
doi: 10.1371/JOURNAL.PONE.0094112
pubmed: 24763306
pmcid: 3998960
Bećarević N, Softić R, Osmanović E (2022) Does the duration of the illness affect the severity of negative symptoms of schizophrenia? Mater Sociomed 34:25–27. https://doi.org/10.5455/MSM.2022.33.25-27
doi: 10.5455/MSM.2022.33.25-27
pubmed: 35801060
pmcid: 9229283
Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA BM (2007) Quality of life in schizophrenic patients. Dialogues Clin Neurosci 9:215–226. https://doi.org/10.31887/DCNS.2007.9.2/JBOBES
Buoli M, Caldiroli A, Panza G, Altamura AC (2012) Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig 9:354–360. https://doi.org/10.4306/PI.2012.9.4.354
doi: 10.4306/PI.2012.9.4.354
pubmed: 23251199
pmcid: 3521111
Carnovale C, Lucenteforte E, Battini V et al (2021) Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med 24:1–13. https://doi.org/10.1017/S0033291721000180
doi: 10.1017/S0033291721000180
Ceraso A, Lin JJ, Schneider-Thoma J et al (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane database Syst Rev 8:CD008016. https://doi.org/10.1002/14651858.CD008016.pub3
doi: 10.1002/14651858.CD008016.pub3
pubmed: 32840872
Cerovecki A, Musil R, Klimke A et al (2013) Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27:545–572. https://doi.org/10.1007/s40263-013-0079-5
doi: 10.1007/s40263-013-0079-5
pubmed: 23821039
Chrzanowski WK, Marcus RN, Torbeyns A et al (2006) Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 189:259–266. https://doi.org/10.1007/s00213-006-0564-3
doi: 10.1007/s00213-006-0564-3
pubmed: 17058105
Curson DA, Barnes TR, Bamber RW et al (1985) Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry 146:474–480. https://doi.org/10.1192/bjp.146.5.474
doi: 10.1192/bjp.146.5.474
pubmed: 3893600
Dayabandara M, Hanwella R, Ratnatunga S et al (2017) Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 13:2231–2241. https://doi.org/10.2147/NDT.S113099
doi: 10.2147/NDT.S113099
pubmed: 28883731
pmcid: 5574691
Emsley R, Chiliza B, Asmal L (2013) The evidence for illness progression after relapse in schizophrenia. Schizophr Res 148:117–121. https://doi.org/10.1016/j.schres.2013.05.016
doi: 10.1016/j.schres.2013.05.016
pubmed: 23756298
Emsley R, Chiliza B, Asmal L, Harvey BH (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:50. https://doi.org/10.1186/1471-244X-13-50
doi: 10.1186/1471-244X-13-50
pubmed: 23394123
pmcid: 3599855
Emsley R, Oosthuizen P, Koen L et al (2013) Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol 33:80–83. https://doi.org/10.1097/JCP.0b013e31827bfcc1
doi: 10.1097/JCP.0b013e31827bfcc1
pubmed: 23277247
Faulkner G, Cohn T, Remington G (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 1:CD005148. https://doi.org/10.1002/14651858.CD005148.pub2
doi: 10.1002/14651858.CD005148.pub2
Furukawa TA, Levine SZ, Tanaka S et al (2015) Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA psychiatry 72:14–21. https://doi.org/10.1001/jamapsychiatry.2014.2127
doi: 10.1001/jamapsychiatry.2014.2127
pubmed: 25372935
Gardner DM, Murphy AL, O’Donnell H et al (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686–693. https://doi.org/10.1176/appi.ajp.2009.09060802
doi: 10.1176/appi.ajp.2009.09060802
pubmed: 20360319
Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (London, England) 394:939–951. https://doi.org/10.1016/S0140-6736(19)31135-3
doi: 10.1016/S0140-6736(19)31135-3
pubmed: 31303314
pmcid: 6891890
Jain S, Bhargava M, Gautam S (2006) Weight gain with olanzapine: Drug, gender or age? Indian J Psychiatry 48:39–42. https://doi.org/10.4103/0019-5545.31617
doi: 10.4103/0019-5545.31617
pubmed: 20703413
pmcid: 2913641
Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (London, England) 371:1085–1097. https://doi.org/10.1016/S0140-6736(08)60486-9
doi: 10.1016/S0140-6736(08)60486-9
pubmed: 18374841
Kane JM, Osuntokun O, Kryzhanovskaya LA et al (2009) A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 70:572–581. https://doi.org/10.4088/jcp.08m04421
doi: 10.4088/jcp.08m04421
pubmed: 19323965
Kane JM, Leucht S, Carpenter D, Docherty JP (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64:5–19. Retrieved from https://www.psychiatrist.com/jcp/
Kasper S (1999) First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 60:5–9. Retrieved from https://www.psychiatrist.com/jcp/
Kinon BJ, Volavka J, Stauffer V et al (2008) Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 28:392–400. https://doi.org/10.1097/jcp.0b013e31817e63a5
doi: 10.1097/jcp.0b013e31817e63a5
pubmed: 18626265
Leucht S, Crippa A, Siafis S et al (2020) Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry 177:342–353. https://doi.org/10.1176/appi.ajp.2019.19010034
doi: 10.1176/appi.ajp.2019.19010034
pubmed: 31838873
Lieberman J, Jody D, Geisler S et al (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369–376. https://doi.org/10.1001/archpsyc.1993.01820170047006
doi: 10.1001/archpsyc.1993.01820170047006
pubmed: 8098203
Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223. https://doi.org/10.1056/NEJMoa051688
doi: 10.1056/NEJMoa051688
pubmed: 16172203
McQuade RD, Stock E, Marcus R et al. (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65:47–56. Retrieved from https://www.psychiatrist.com/jcp/
Meltzer HY, Bobo WV, Roy A et al (2008) A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69:274–285. https://doi.org/10.4088/jcp.v69n0214
doi: 10.4088/jcp.v69n0214
pubmed: 18232726
Obayashi Y, Mitsui S, Sakamoto S et al (2020) Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology (Berl) 237:167–175. https://doi.org/10.1007/s00213-019-05352-7
doi: 10.1007/s00213-019-05352-7
pubmed: 31624859
Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry 7:64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
doi: 10.1016/S2215-0366(19)30416-X
pubmed: 31860457
pmcid: 7029416
Robinson D, Woerner MG, Alvir JMJ et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247. https://doi.org/10.1001/archpsyc.56.3.241
doi: 10.1001/archpsyc.56.3.241
pubmed: 10078501
Schneider-Thoma J, Chalkou K, Dörries C et al (2022) Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet (London, England) 399:824–836. https://doi.org/10.1016/S0140-6736(21)01997-8
doi: 10.1016/S0140-6736(21)01997-8
pubmed: 35219395
Shimomura Y, Kikuchi Y, Suzuki T et al (2020) Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophr Res 215:8–16. https://doi.org/10.1016/j.schres.2019.09.013
doi: 10.1016/j.schres.2019.09.013
pubmed: 31784340
Stern RG, Kahn RSDM (1993) Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 16:313–338. https://doi.org/10.1016/S0193-953X(18)30176-X
doi: 10.1016/S0193-953X(18)30176-X
pubmed: 8101371
Teasdale SB, Ward PB, Rosenbaum S et al (2017) Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 210:110–118. https://doi.org/10.1192/bjp.bp.115.177139
doi: 10.1192/bjp.bp.115.177139
pubmed: 27810893
Thompson A, Winsper C, Marwaha S et al (2018) Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych open 4:215–225. https://doi.org/10.1192/bjo.2018.17
doi: 10.1192/bjo.2018.17
pubmed: 29988997
pmcid: 6034451
Üçok A, Kara İA (2020) Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. Schizophr Res 225:31–38. https://doi.org/10.1016/j.schres.2019.10.015
doi: 10.1016/j.schres.2019.10.015
pubmed: 31653578
Zhu Y, Li C, Huhn M et al (2017) How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol 27:835–844. https://doi.org/10.1016/j.euroneuro.2017.06.011
doi: 10.1016/j.euroneuro.2017.06.011
pubmed: 28669774